Pfizer Celebrex Polyp Trials Get Added Weight With Vioxx Withdrawal
Executive Summary
Two trials for the COX-2 inhibitor Celebrex in prevention of adenomatous polyps take on added significance following Merck's withdrawal of Vioxx
You may also be interested in...
Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data
The effect of the Vioxx withdrawal on the non-steroidal anti-inflammatory drug market will likely be determined by long-term studies of marketed products